###
###
###Bio-Raid###
###
所有分类

论文

  • 分类:1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 3,4, 4, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2,1,2, 1,2, 1,2, 1,2, 1,2, 5, 1,2, 3,4, 1,2, 1,2.

     2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017.

     

    Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients.

    1111111111123.
     
      2020 Jan 23;10(1):8. doi: 10.1038/s41408-020-0274-9.
     

    Entecavir Prophylaxis for Hepatitis B Virus Reactivation in Patients with CAR T-cell Therapy.

    1234541116615755.
     
     2020 Apr 14. pii: blood.2020004907. doi: 10.1182/blood.2020004907.
     
     

    Efficacy and Toxicity for CD22/CD19 Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed/Refractory Aggressive B-cell Lymphoma Involving the Gastrointestinal Tract

    Chen Zeng 1, Jiali Cheng 1, Tongjuan Li 1, Jin Huang 1, Chunrui Li 1, Lijun Jiang 1, Jue Wang 1, Liting Chen 1, Xia Mao 1, Li Zhu 1, Yaoyao Lou 1, Jianfeng Zhou 1, Xiaoxi Zhou 2
     
    Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13
     
     

    Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy

     DOI: 10.1002/ctm2.176

                                                                                                      

    A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

扫二维码用手机看